Pathogenesis of marrow fibrosis in myeloproliferative disorders (MPD);Patogeneza wŁóknienia szpiku w zespole mieloproliferacyjnym (ZM)

Polskie Archiwum Medycyny Wewnetrznej

Volumn 99, Issue 1, 1998, Pages 70-77

  Wróbel, Tomasz ^a   Podolak Dawidziak, Maria ^a  

^a Katedra i Klinika Hematologii   (Poland)

Author keywords

Fibroblast; Megakaryocytes; Meloproliferative disorders; Myelofibrosis

Indexed keywords

GROWTH PROMOTOR;

HUMAN; METABOLISM; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; REVIEW;

GROWTH SUBSTANCES; HUMANS; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDERS;

EID: 0031609452     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Smith R.E., Chelmowski M.K., Szabo E.J. Myelofibrosis: a concise review of clinical and pathologic features and treatment. Am. J. Hematol., 1988, 29, 174.
2. Jacobson R.J., Salo A., Fialkow P.J. Agnogenic myeloid metaplasia: a clonal proliferation a hematopoietic stem cell with secondary myelofibrosis. Blood, 1978, 51, 189.
3. Pereira A., Cervantes F., Brugues R., Rozman C.: Bone marrow histopathology in primary myelofibrosis: clinical and hematologic correlations and prognostic evaluation. Eur. J. Haematol., 1990, 44, 94.
4. Caligaris Cappio F., Vigliani R., Novarino A., Camussi G., Campana D., Gavosto F.: Idiopathic myelofibrosis: a possible role for immune-complexes in the pathogenesis of bone marrow fibrosis. Br. J. Haematol., 1981, 49, 17.
5. Wolf B.C., Neiman R.S.: The bone marrow in myeloproliferative and dysmyelopoietic syndromes. Hemat/Oncology North. Am., 1988, 2, 669.
6. Bartl R., Frisch B., Baungart R.: Morphologic classification of the myelodysplastic syndromes (MDS): combined utilisation of bone marrow aspirates and trophine biopsies. Leukaemia Res., 1992, 16, 15.
7. McCarthy D.: Annonation. Fibrosis of the bone marrow: content and causes. Brit. J. Haematol., 1985, 59, 1.
8. Frisch B., Lewis S.M., Burkhardt R., Bartl R.: Myeloproliferative disorders. w: Biopsy pathology of bone and bone marrow. Chapman and Hall, London, 1985, 108.
9. Robak T.: Współczesne pogla+ (combining ogonek sign)dy na patogeneze+ (combining ogonek sign) i leczenie samoistnej (pierwotnej mielofibrozy. Polski Tyg. Lek., 1992, 47, 144.
10. Reilly J.T.: Pathogenesis of idiopathic myelofibrosis: present status and future directions. Brit. J. Haematol., 1994, 88, 1.
11. Lewis S.M., Szur L.: Malignant myelosclerosis. Br Med. J., 1963, 2, 472.
12. Bird T., Proctor S.J.: Malignant myelosclerosis. Myeloproliferative disorder or leukemia? Am. J. Clin. Path., 1977, 67, 512.
13. Charron D., Robert L., County M.C., Binet J.L.: Biochemical and histological analysis of bone marrow collagen in myelofibrosis. Br. J. Haematol., 1979, 41, 151
14. Reilly J.T., Nash J R.G., Mackie M.J., McVerry B.A.: Endothelial cell proliferation in myelofibrosis. Br. J. Haematol., 1985, 60, 625.
15. Georgii A., Vykoupil K.F., Buhr T. i wsp.: Chronic myeloproliferative disorders in bone marrow biopsies. Path. Res. Pract., 1990, 186, 3.
16. Buhr T., Georgii A., Choritz H.: Myelofibrosis in chronic myeloproliferative disorders. Incidence among subtypes according to the Hannover Classification. Path. Res. Pact., 1993, 189, 121.
17. Thiele J., Rompcik V., Wagner S.T., Fischer R.: Vascular architecture and collagen type IV in primary myelofibrosis and polycythaemia vera: An immunomorphometric study on trophine biopsies of the bone marrow. Br. J. Haematol., 1992, 80, 227.
18. Bartl R., Frisch B , Wilmanns W.: Potential of bone marrow biopsy in chronic myeloproliferative disorders (MPD). Eur. J Haematol., 1993, 50, 41.
19. Ayad S., Boot-Handford R.P., Humphries M.J., Kadler K.E., Shuttleworth C.A.: The extracellular matrix. Facts book, Academic Harcourt Brace & Company, Publ., London San Diego New York Boston Sydney Tokyo Toronto, 1994.
20. Miyazono K , Takaku F. Platelet derived growth factors. Blood Rev., 1989, 3, 269.
21. Friedenstein A.J., Gorskaja U.F., Kulagina N.N.: Fibroblasts precursors in normal and irradiated mouse hemietic organs. Exp. Hematol., 1976, 2, 83.
22. Castro-Malaspina H., Rabellino E., Yen A., Nachman R., Moore M.A.S.: Human megakaryocyte stimulation of proliferation of bone marrow fibroblasts, Blood, 1981, 57, 781.
23. Castro-Malaspina H., Gay R.E., Jhanvar S.C. i wsp.: Characteristics of bone marrow fibroblast colony - forming cells (CFU-F) and their progeny in patientst with myeloproliferative disorders. Blood, 1982, 59, 1046.
24. Mayani H., Guilbert L., Janowska-Wieczorek A.: Biology of the hemopoietic microenvironment. Eur. J. Haematol., 1992, 49, 225.
25. Hardy C.L., Megason G.C.: Specificity of hematopoietic stem cell homing. Hematol. Oncology, 1996, 14, 17
26. Gordon M.Y., Lewis J.L., Marley S.B., Grand F.M., Goldman J.M.: Stromal cells negatively regulate haematopoietic progenitos activation via a phosphatidylinositolanchored cell adhesion signaling mechanism. Brit. J Haematol. 1997, 96, 647.
27. Greenberg B., Woo L., Veomett I. Cytogenetics of bone marrow fibroblastic cells in idiopathic chronic myelofibrosis. Brit. J. Haematol., 1987, 66, 487.
28. Kimura A., Katoh O., Hyodo H., Kuramoto A., Satow Y. Platelet derived growth factor expression, myelofibrosis and chronic myelogenous leukemia Leukemia and Lymphoma, 1995, 18, 237
29. Castro-Malaspina H., Moore M.A.S.: Pathophysiological mechanisms operating in the development of myelofibrosis: role of megakaryocytes. Nouv. Rev. Fr. Hematol., 1982, 24, 221.
30. Hickling R.A.: Chronic non-leukaemic myelosis. Q. J Med., 1937, 6, 253.
31. Burkhardt R , Bartl R M , Beil E i wsp.: Myelofibrosis- osteosclerosis syndrome. Review of literature and histomorphometry. Advances in the Biosciences, Oxford/Braunschweig: Pergamon Press/Vieweg, 1975, 16, 9.
32. Farese A.M., Hunt P., Boone T., MacVittie T.J. Recombinant human megakaryocyte growth and development factors stimulates megakaryocytopoiesis in normal non human primates. Blood, 86, 54
33. Kaushansky K. Trombopoietin: the primary regulator of platelet production. Blood, 1995, 86, 419.
34. Yan X-G., Lacey D., Fietcher F. i wsp.: Chronic exposure to retroviral vector encoded MGDF (mpl ligand) induces lieage - specific growth and differentiation of megakaryocytes in mice. Blood, 1995, 86, 4025
35. Cohen-Solal K., Villeval J-L., Debili N., Vainchenker W., Wendling F.: Platelet production and its control, Education Programme Eur. Haematol. Ass., Blackwell Science Ltd, London, 1996, 24.
36. Podolak-Dawidziak M.: Trombopoetyna. w: Cytokiny. Zastosowanie kliniczne. red. W. W. Je+ (combining ogonek sign)drzejczak, M. Podolak-Dawidziak, Volumed, Wrocław, 1997, 103.
37. Katoh O., Kimura A., Kuramoto A.: Platelet - derived growth factor is decreased in patients with myeloproliferative disorders. Am. J. Hemat., 1988, 27, 276.
38. Jacobsen S.E.W., Ruscetti F.W., Dubois C.M. i wsp.: Transforming growth factor-ß transmodulates the expression of colony stimulating factors on murine hematopoietic progenitor cell lines, Blood, 1991a, 77, 1706.
39. Ruscetti F.W., Dubois C.M., Jacobsen S.E.W., Keller J.R.: Transforming growth factor ß and interleukin-1: a paradigm for opposing regulation of haemopoiesis, Bailiere's Clin. Haematol., 1992, 5, 703.
40. Kimura A., Hyodo H., Nakata Y.: Chronic lymphocytic leukemia associated with bone marrow fibrosis: possible role of interleukin 1 alpha in the pathogenesis. Am. J. Hematol., 1993, 43, 47.
41. Rowe P.M.: Clinical potential for TGF-ß. Lancet, 1994, 344, 72.
42. Kimura A., Katoh O., Kuramoto A.: Effects of platelet derived growth factor, epidermal growth factor and transforming growth vactor beta on the growth of human marrow fibroblasts. Brit. J. Haematol., 1988, 69, 9.
43. Han Z.C., Belluci S., Wan H.Y.: New insights into the regulation of megakaryocytopoiesis by haematopoietic and fibroblastic growth factors and transforming growth factor ß1, Brit. J. Haematol., 1992, 81, 1.
44. Hannocks M.J., Olivier L., Gabrilove J.: Regulation of proteolytic activity in human bone marrow stromal cells by basic fibroblast growth factor, interleukin-1 and transforming growth factor b. Blood, 1992, 79, 1178.
45. Li Y., Hetet G., Maurer A.M.: Spontaneous megakaryocyte colony formation in myeloproliferative disorders is not meutralizable by antibodies against I13, I16 and GM-CSF. Brit. J. Haemat., 1994, 87, 471.
46. Gospodarowicz D., Cheng J.: Heparin protects basic and acidic FGF from inactivation. J. Cell Physiol., 1986, 1, 475.
47. le Querrec A., Duval D., Tobelem G.: Tumor angiogenesis, Baillere's Clin. Haematol., 1993, 6, 711.
48. Thiele J., Kvasnicka H.M., Fischer R., Diehl V.: Clinicopathological impacts of the interaction between megakaryocytes and myeloid stroma in chronic myeloproliferative disorders: a concise update, leukemia and Lymphoma, 1997, 24, 463.